Hemady®
Drugs - Hemady® (dexamethasone) [Edenbridge Pharmaceuticals, LLC.]
January 2025
Therapeutic area - Glucocorticoids, Oral
Initial approval criteria:
- Patient must be at least 18 years of age AND Patient must have a diagnosis of multiple myeloma AND
- Hemady must be prescribed in combination with other anti-myeloma products AND
- Patient must not be experiencing a systemic fungal infection AND
- Hemady is prescribed by, or in consultation, with an oncologist AND
- Patient has had a trial and failure, intolerance, or contraindication to generic dexamethasone oral tablets.
Renewal criteria:
- Patient continues to meet the initial approval criteria AND
- Documentation of positive clinical response is provided at time of request
Quantity limits
- 20 mg or 40 mg orally once daily, on specific days depending on the protocol regimen
- Documentation of the protocol regimen must be provided at time of request
Questions?
Provider Call Center (844) 575-7887
